A Phase 1a, Randomized, Double-blinded, Placebo-Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ELX-02 in Healthy Adult Volunteers
Phase of Trial: Phase I
Latest Information Update: 08 Mar 2019
Price : $35 *
At a glance
- Drugs ELX 02 (Primary) ; ELX 02 (Primary)
- Indications Cystic fibrosis; Cystinosis; Duchenne muscular dystrophy; Inborn genetic disorders; Mucopolysaccharidosis I; Rett syndrome
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eloxx Pharmaceuticals
- 08 Mar 2019 According to an Eloxx Pharmaceuticals media release, results from the phase 1a single-ascending dose (SAD) study for ELX-02 (NCT02807961 and NCT03292302) have been published in the January 2019 edition of the Journal of Clinical Pharmacology and Drug Development.
- 08 Nov 2018 According to an Eloxx Pharmaceutical media release, the results have been submitted to a scientific journal for publication.
- 19 Mar 2018 According to an Eloxx Pharmaceutical media release, results from the completed Phase 1 SAD study (NCT02807961 and NCT03292302) will be included in the planned IND and CTA submissions.